Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry

Hafsah Nabi; Oliver Hendricks; Dorte Vendelbo Jensen; Anne Gitte Loft; Jens Pedersen; Søren Andreas Just; Kamilla  Danebod; Heidi Lausten  Munk; Salome Kristensen; Natalia Manilo; Ada Colic; Asta  Linauskas; Pia Høger Thygesen; Louise Christensen; Maren Høgberget Kalisz; Niels Lomborg; Stavros Chrysidis; Johnny Lillelund Raun; Marlene Andersen; Frank Mehnert; Niels Steen Krogh; Merete Lund Hetland; Bente Glintborg

Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry

Hafsah Nabi, Oliver Hendricks, Dorte Vendelbo Jensen, Anne Gitte Loft, Jens Pedersen, Søren Andreas Just, Kamilla Danebod, Heidi Lausten Munk, Salome Kristensen, Natalia Manilo, Ada Colic, Asta Linauskas, Pia Høger Thygesen, Louise Christensen, Maren Høgberget Kalisz, Niels Lomborg, Stavros Chrysidis, Johnny Lillelund Raun, Marlene Andersen, Frank MehnertNiels Steen Krogh, Merete Lund Hetland, Bente Glintborg

Abstract

Background/Purpose:
In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from originator infliximab to corresponding biosimilar in patients with inflammatory rheumatic diseases (1). However, the outcomes after switching from one infliximab biosimilar to a second infliximab biosimilar remain scarcely investigated. Denmark has recently conducted a nationwide mandatory infliximab biosimilar-to-biosimilar switch. In this study, we aimed to investigate the effectiveness of switching infliximab biosimilars CT-P13-to-GP1111 among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA), including patients who had previously switched from originator (originator-experienced) to CT-P13 as well as patients who were originator-naïve.

Original language	English
Publication date	2022
Publication status	Published - 2022
Event	ACR 2022 - Philadelphia Duration: 10 Nov 2022 → 14 Nov 2022

Conference

Conference	ACR 2022
City	Philadelphia
Period	10/11/2022 → 14/11/2022

Cite this

Nabi, H., Hendricks, O., Jensen, D. V., Loft, A. G., Pedersen, J., Just, S. A., Danebod, K., Munk, H. L., Kristensen, S., Manilo, N., Colic, A., Linauskas, A., Thygesen, P. H., Christensen, L., Kalisz, M. H., Lomborg, N., Chrysidis, S., Raun, J. L., Andersen, M., ... Glintborg, B. (2022). Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry. Arthritis & Reumatology Vol. 74, number S9, p. 2209. Abstract from ACR 2022, Philadelphia.

Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry. / Nabi, Hafsah; Hendricks, Oliver; Jensen, Dorte Vendelbo et al.
2022. Arthritis & Reumatology Vol. 74, number S9, p. 2209 Abstract from ACR 2022, Philadelphia.

Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

Nabi, H, Hendricks, O, Jensen, DV, Loft, AG, Pedersen, J, Just, SA, Danebod, K , Munk, HL, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, PH, Christensen, L, Kalisz, MH, Lomborg, N, Chrysidis, S, Raun, JL, Andersen, M, Mehnert, F, Krogh, NS, Hetland, ML & Glintborg, B 2022, 'Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry', ACR 2022, Philadelphia, 10/11/2022 - 14/11/2022 pp. Arthritis & Reumatology Vol. 74, number S9, p. 2209.

@conference{8c22b350aaa148bc85cd80d97f05a360,

title = "Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry",

abstract = "Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from originator infliximab to corresponding biosimilar in patients with inflammatory rheumatic diseases (1). However, the outcomes after switching from one infliximab biosimilar to a second infliximab biosimilar remain scarcely investigated. Denmark has recently conducted a nationwide mandatory infliximab biosimilar-to-biosimilar switch. In this study, we aimed to investigate the effectiveness of switching infliximab biosimilars CT-P13-to-GP1111 among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA), including patients who had previously switched from originator (originator-experienced) to CT-P13 as well as patients who were originator-na{\"i}ve.",

author = "Hafsah Nabi and Oliver Hendricks and Jensen, {Dorte Vendelbo} and Loft, {Anne Gitte} and Jens Pedersen and Just, {S{\o}ren Andreas} and Kamilla Danebod and Munk, {Heidi Lausten} and Salome Kristensen and Natalia Manilo and Ada Colic and Asta Linauskas and Thygesen, {Pia H{\o}ger} and Louise Christensen and Kalisz, {Maren H{\o}gberget} and Niels Lomborg and Stavros Chrysidis and Raun, {Johnny Lillelund} and Marlene Andersen and Frank Mehnert and Krogh, {Niels Steen} and Hetland, {Merete Lund} and Bente Glintborg",

note = "COPECARE; ACR 2022 ; Conference date: 10-11-2022 Through 14-11-2022",

year = "2022",

language = "English",

pages = "Arthritis & Reumatology Vol. 74, number S9, p. 2209",

}

TY - ABST

T1 - Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry

AU - Nabi, Hafsah

AU - Hendricks, Oliver

AU - Jensen, Dorte Vendelbo

AU - Loft, Anne Gitte

AU - Pedersen, Jens

AU - Just, Søren Andreas

AU - Danebod, Kamilla

AU - Munk, Heidi Lausten

AU - Kristensen, Salome

AU - Manilo, Natalia

AU - Colic, Ada

AU - Linauskas, Asta

AU - Thygesen, Pia Høger

AU - Christensen, Louise

AU - Kalisz, Maren Høgberget

AU - Lomborg, Niels

AU - Chrysidis, Stavros

AU - Raun, Johnny Lillelund

AU - Andersen, Marlene

AU - Mehnert, Frank

AU - Krogh, Niels Steen

AU - Hetland, Merete Lund

AU - Glintborg, Bente

N1 - COPECARE

PY - 2022

Y1 - 2022

N2 - Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from originator infliximab to corresponding biosimilar in patients with inflammatory rheumatic diseases (1). However, the outcomes after switching from one infliximab biosimilar to a second infliximab biosimilar remain scarcely investigated. Denmark has recently conducted a nationwide mandatory infliximab biosimilar-to-biosimilar switch. In this study, we aimed to investigate the effectiveness of switching infliximab biosimilars CT-P13-to-GP1111 among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA), including patients who had previously switched from originator (originator-experienced) to CT-P13 as well as patients who were originator-naïve.

AB - Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from originator infliximab to corresponding biosimilar in patients with inflammatory rheumatic diseases (1). However, the outcomes after switching from one infliximab biosimilar to a second infliximab biosimilar remain scarcely investigated. Denmark has recently conducted a nationwide mandatory infliximab biosimilar-to-biosimilar switch. In this study, we aimed to investigate the effectiveness of switching infliximab biosimilars CT-P13-to-GP1111 among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA), including patients who had previously switched from originator (originator-experienced) to CT-P13 as well as patients who were originator-naïve.

M3 - Conference abstract for conference

SP - Arthritis & Reumatology Vol. 74, number S9, p. 2209

T2 - ACR 2022

Y2 - 10 November 2022 through 14 November 2022

ER -

Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry

Abstract

Conference

Fingerprint

Cite this